UPDATE: Sterne Agee Downgrades Albany Molecular Research on Less Optimism in Core Business Value
December 03, 2013 at 08:27 AM EST
In a report published Tuesday, Sterne Agee analyst Greg T. Bolan downgraded the rating on Albany Molecular Research (NASDAQ: AMRI ) from Buy to Neutral, and lowered the price target from $15.00 to $12.00. In the report, Sterne Agee noted, “As we have written multiple times, we believe CRO valuations
